238 related articles for article (PubMed ID: 26701727)
1. Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.
Yang S; Luo C; Gu Q; Xu Q; Wang G; Sun H; Qian Z; Tan Y; Qin Y; Shen Y; Xu X; Chen SH; Chan CC; Wang H; Mao M; Fang DD
Oncotarget; 2016 Feb; 7(5):5461-9. PubMed ID: 26701727
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.
Mohan CD; Bharathkumar H; Bulusu KC; Pandey V; Rangappa S; Fuchs JE; Shanmugam MK; Dai X; Li F; Deivasigamani A; Hui KM; Kumar AP; Lobie PE; Bender A; Basappa ; Sethi G; Rangappa KS
J Biol Chem; 2014 Dec; 289(49):34296-307. PubMed ID: 25320076
[TBL] [Abstract][Full Text] [Related]
3. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
4. CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling.
Yang L; Xue H; Sun Y; Zhang L; Xue F; Ge R
Cell Death Dis; 2020 Jul; 11(7):605. PubMed ID: 32732872
[TBL] [Abstract][Full Text] [Related]
5. LINC00346 promotes hepatocellular carcinoma progression via activating the JAK-STAT3 signaling pathway.
Yin YZ; Zheng WH; Zhang X; Chen YH; Tuo YH
J Cell Biochem; 2020 Jan; 121(1):735-742. PubMed ID: 31478228
[TBL] [Abstract][Full Text] [Related]
6. Total alkaloids of Rubus aleaefolius Poir. inhibit the STAT3 signaling pathway leading to suppression of proliferation and cell cycle arrest in a mouse model of hepatocellular carcinoma.
Zhao J; Lin W; Cao Z; Liu L; Zhuang Q; Zhong X; Hong Z; Peng J
Oncol Rep; 2013 Sep; 30(3):1309-14. PubMed ID: 23828071
[TBL] [Abstract][Full Text] [Related]
7. LLL12, a novel small inhibitor targeting STAT3 for hepatocellular carcinoma therapy.
Zuo M; Li C; Lin J; Javle M
Oncotarget; 2015 May; 6(13):10940-9. PubMed ID: 25883212
[TBL] [Abstract][Full Text] [Related]
8. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
9. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3.
Huang S; Zhou D; Li YX; Ming ZY; Li KZ; Wu GB; Chen C; Zhao YN
J Cell Physiol; 2019 Apr; 234(4):3500-3514. PubMed ID: 30370582
[TBL] [Abstract][Full Text] [Related]
11. Extract of
Huang X; Chen Y; Zhang X; Li F; Ye H
Cancer Biother Radiopharm; 2020 Oct; 35(8):586-595. PubMed ID: 32486841
[No Abstract] [Full Text] [Related]
12. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
13. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
14. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of penta-O-galloyl-β-D-glucose suppresses triple-negative breast cancer xenograft growth and metastasis in strong association with JAK1-STAT3 inhibition.
Lee HJ; Seo NJ; Jeong SJ; Park Y; Jung DB; Koh W; Lee HJ; Lee EO; Ahn KS; Ahn KS; Lü J; Kim SH
Carcinogenesis; 2011 Jun; 32(6):804-11. PubMed ID: 21289371
[TBL] [Abstract][Full Text] [Related]
16. Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Wang H; Hou W; Perera A; Bettler C; Beach JR; Ding X; Li J; Denning MF; Dhanarajan A; Cotler SJ; Joyce C; Yin J; Ahmed F; Roberts LR; Qiu W
Cell Rep; 2021 Feb; 34(8):108765. PubMed ID: 33626345
[TBL] [Abstract][Full Text] [Related]
17. A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway.
Zhao H; Guo Y; Li S; Han R; Ying J; Zhu H; Wang Y; Yin L; Han Y; Sun L; Wang Z; Lin Q; Bi X; Jiao Y; Jia H; Zhao J; Huang Z; Li Z; Zhou J; Song W; Meng K; Cai J
Oncotarget; 2015 Oct; 6(31):31927-43. PubMed ID: 26376676
[TBL] [Abstract][Full Text] [Related]
18. miR-30e acts as a tumor suppressor in hepatocellular carcinoma partly via JAK1/STAT3 pathway.
Mao J; Hu X; Pang P; Zhou B; Li D; Shan H
Oncol Rep; 2017 Jul; 38(1):393-401. PubMed ID: 28560434
[TBL] [Abstract][Full Text] [Related]
19. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells.
Wonganan O; He YJ; Shen XF; Wongkrajang K; Suksamrarn A; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2017 Dec; 336():31-39. PubMed ID: 29031523
[TBL] [Abstract][Full Text] [Related]
20. Genipin suppression of growth and metastasis in hepatocellular carcinoma through blocking activation of STAT-3.
Hong M; Lee S; Clayton J; Yake W; Li J
J Exp Clin Cancer Res; 2020 Aug; 39(1):146. PubMed ID: 32741371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]